<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG, Biologics Innovation Group. To nurture an Eco-system for Biologics innovation and imprint China on Global map.</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 20 Apr 2021 21:28:03 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>轻重链错配？双特异抗体技术平台中的Linker策略</title><link>https://mp.weixin.qq.com/s/qes8ssug4ttGWtxrDX3pGw</link><description></description><content:encoded><![CDATA[轻重链错配？双特异抗体技术平台中的Linker策略]]></content:encoded><pubDate>Tue, 20 Apr 2021 20:14:54 +0800</pubDate></item><item><title>议程首发｜首届中国生物计算大会举办在即，李彦宏邀数位院士专家共议行业未来！</title><link>https://mp.weixin.qq.com/s/fRx9uNdsF9L0k69Xat850Q</link><description></description><content:encoded><![CDATA[议程首发｜首届中国生物计算大会举办在即，李彦宏邀数位院士专家共议行业未来！]]></content:encoded><pubDate>Tue, 20 Apr 2021 20:14:54 +0800</pubDate></item><item><title>类风湿关节炎：生物药热潮渐退，JAK机会来了？</title><link>https://mp.weixin.qq.com/s/I0XBAuGgvNeo0gL7egctjA</link><description></description><content:encoded><![CDATA[类风湿关节炎：生物药热潮渐退，JAK机会来了？]]></content:encoded><pubDate>Sun, 18 Apr 2021 10:03:18 +0800</pubDate></item><item><title>创新蓝海，百药争鸣｜BiG七周年半壁江山阵容揭秘</title><link>https://mp.weixin.qq.com/s/jz_r9zlH-vDkivnmn1mIWA</link><description></description><content:encoded><![CDATA[创新蓝海，百药争鸣｜BiG七周年半壁江山阵容揭秘]]></content:encoded><pubDate>Fri, 16 Apr 2021 16:43:45 +0800</pubDate></item><item><title>新江湖｜凌腾医药加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/o-qVmqn_fv7LAhjRZPVrRw</link><description></description><content:encoded><![CDATA[新江湖｜凌腾医药加入BiG会员机构！]]></content:encoded><pubDate>Fri, 16 Apr 2021 16:43:45 +0800</pubDate></item><item><title>肠道微生物，后PD-1免疫时代的另辟蹊径</title><link>https://mp.weixin.qq.com/s/fT__xjpBOPNZ7QsqUGbBZQ</link><description></description><content:encoded><![CDATA[肠道微生物，后PD-1免疫时代的另辟蹊径]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:36:10 +0800</pubDate></item><item><title>春天的故事丨春天Proswell总裁兼创始人宋青春受邀《Pharma Tech Outlook》专访</title><link>https://mp.weixin.qq.com/s/2IOO7ANYE64H-nNTbwAxlQ</link><description></description><content:encoded><![CDATA[春天的故事丨春天Proswell总裁兼创始人宋青春受邀《Pharma Tech Outlook》专访]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:36:10 +0800</pubDate></item><item><title>抗体前沿碰撞RNA疗法｜BiG春季聚会*苏州站</title><link>https://mp.weixin.qq.com/s/AC3VrzKgCby6OAeJhfPFMA</link><description></description><content:encoded><![CDATA[抗体前沿碰撞RNA疗法｜BiG春季聚会*苏州站]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:36:10 +0800</pubDate></item><item><title>下一代mRNA疫苗技术创新</title><link>https://mp.weixin.qq.com/s/5yNx4zGMiykKCpHGLPyOgA</link><description></description><content:encoded><![CDATA[下一代mRNA疫苗技术创新]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:14:03 +0800</pubDate></item><item><title>又一里程碑！凌腾医药卡妥索双抗膀胱癌IND获批</title><link>https://mp.weixin.qq.com/s/8Cy-cj3qyK2cqJXOB9vGWw</link><description></description><content:encoded><![CDATA[又一里程碑！凌腾医药卡妥索双抗膀胱癌IND获批]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:14:03 +0800</pubDate></item><item><title>新江湖｜杨璐菡、肖溯、何立峰、刘宁姝、张敬加入BiG！</title><link>https://mp.weixin.qq.com/s/ej0E_m776Ww_X8sMFIp_DA</link><description></description><content:encoded><![CDATA[新江湖｜杨璐菡、肖溯、何立峰、刘宁姝、张敬加入BiG！]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:14:03 +0800</pubDate></item><item><title>罗氏新型Prot-2+1 TCB抗体</title><link>https://mp.weixin.qq.com/s/F6yqVgGCkU616vrS0-YtfQ</link><description></description><content:encoded><![CDATA[罗氏新型Prot-2+1 TCB抗体]]></content:encoded><pubDate>Mon, 12 Apr 2021 17:00:33 +0800</pubDate></item><item><title>一匹黑马！DJSeedin创新合作峰会进入倒计时</title><link>https://mp.weixin.qq.com/s/lj-zyF3V2FIS1Wbdh14ShA</link><description></description><content:encoded><![CDATA[一匹黑马！DJSeedin创新合作峰会进入倒计时]]></content:encoded><pubDate>Mon, 12 Apr 2021 17:00:33 +0800</pubDate></item><item><title>国内CAR-T：三种研发模式齐飞，临床应用困境仍在！</title><link>https://mp.weixin.qq.com/s/-PXjMrMT6Qzv7YH28C8BJQ</link><description></description><content:encoded><![CDATA[国内CAR-T：三种研发模式齐飞，临床应用困境仍在！]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:54:57 +0800</pubDate></item><item><title>抗体前沿碰撞RNA疗法｜暨逻晟研发中心落成庆典</title><link>https://mp.weixin.qq.com/s/Q_-BdtpgwDa1pOmb-a22wA</link><description></description><content:encoded><![CDATA[抗体前沿碰撞RNA疗法｜暨逻晟研发中心落成庆典]]></content:encoded><pubDate>Thu, 08 Apr 2021 19:00:12 +0800</pubDate></item><item><title>ALL和NHL领域，临床开发中的双特异抗体</title><link>https://mp.weixin.qq.com/s/gjCv8FLgTlfFhK41VpN8DQ</link><description></description><content:encoded><![CDATA[ALL和NHL领域，临床开发中的双特异抗体]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:16:19 +0800</pubDate></item><item><title>BiG现场｜站在巨人肩膀，ADC药物研发策略的重点！</title><link>https://mp.weixin.qq.com/s/xBOrY-gT3YWXUiEhPDHI3A</link><description></description><content:encoded><![CDATA[BiG现场｜站在巨人肩膀，ADC药物研发策略的重点！]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:16:19 +0800</pubDate></item><item><title>荐 | 临床大咖齐聚苏州，共创新药研发良好生态！</title><link>https://mp.weixin.qq.com/s/GsucUnZuZLTQw1YqWVOFiA</link><description></description><content:encoded><![CDATA[荐 | 临床大咖齐聚苏州，共创新药研发良好生态！]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:16:19 +0800</pubDate></item><item><title>TIGIT+记忆B细胞在免疫调节中的作用</title><link>https://mp.weixin.qq.com/s/HoFyIocScfkGO5aMJkZcMw</link><description></description><content:encoded><![CDATA[TIGIT+记忆B细胞在免疫调节中的作用]]></content:encoded><pubDate>Tue, 06 Apr 2021 20:01:39 +0800</pubDate></item></channel></rss>